Welcome to RxBio, Inc.
A biotech company based on a Broad Platform of Novel and Proprietary Technology.
Recently, a primary focus of RxBio has been developing its lead compound, Rx100, for use in mitigation of gastro-intestinal acute radiation syndrome (GI-ARS). GI-ARS follows exposure to potentially lethal ionizing radiation. GI-ARS occurs as a result of nuclear-weapon detonation, during manufacture and development of nuclear energy materials and following nuclear accidents. Government estimates are that up to many thousands of persons would be at risk of developing ARS following detonation of an improvised nuclear device. Treating GI-ARS is the current limiting step in survival. There is no current therapy for this devastating and life-threatening condition.
RxBio also has preliminary data showing efficacy of Rx100 in models of cholera toxin (CTX)-induced secretory diarrhea and NSAID-induced stomach erosions (e.g., aspirin).
RxBio’s pipeline consists of additional compounds that have shown efficacy in treating ARS, inflammatory conditions, and glioma – a universally fatal form of brain cancer.